Clinical study on treatment of primary headache with liver-yang hyperactivity syndrome by He-Sea acupoints

注册号:

Registration number:

ITMCTR2100004357

最近更新日期:

Date of Last Refreshed on:

2021-01-30

注册时间:

Date of Registration:

2021-01-30

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

合穴处方治疗肝阳上亢型原发性头痛临床研究

Public title:

Clinical study on treatment of primary headache with liver-yang hyperactivity syndrome by He-Sea acupoints

注册题目简写:

English Acronym:

研究课题的正式科学名称:

合穴处方治疗肝阳上亢型原发性头痛临床研究

Scientific title:

Clinical study on treatment of primary headache with liver-yang hyperactivity syndrome by He-Sea acupoints

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100042868 ; ChiMCTR2100004357

申请注册联系人:

颜纯淳

研究负责人:

贾红玲

Applicant:

Chunchun Yan

Study leader:

Hongling Jia

申请注册联系人电话:

Applicant telephone:

+86 15665830991

研究负责人电话:

Study leader's telephone:

+86 18254178199

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2889832633@qq.com

研究负责人电子邮件:

Study leader's E-mail:

18254178199@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山东省济南市长清区大学路4655号

研究负责人通讯地址:

山东省济南市市中区经八路1号

Applicant address:

4655 Daxue Road, Changqing District, Ji’nan, Shandong, China

Study leader's address:

1 Jingba Road, Shizhong District, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东中医药大学

Applicant's institution:

Shandong University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020-043-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

山东中医药大学第二附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/9/23 0:00:00

伦理委员会联系人:

张铁峰

Contact Name of the ethic committee:

Tiefeng Zhang

伦理委员会联系地址:

山东省济南市市中区经八路1号

Contact Address of the ethic committee:

1 Jingba Road, Shizhong District, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东中医药大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Shandong University of Chinese Medicine

研究实施负责(组长)单位地址:

山东省济南市市中区经八路1号

Primary sponsor's address:

1 Jingba Road, Shizhong District, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学第二附属医院

具体地址:

市中区经八路1号

Institution
hospital:

The Second Affiliated Hospital of Shandong University of Chinese Medicine

Address:

1 Jingba Road, Shizhong District

经费或物资来源:

国家自然科学基金面上项目(81973695)

Source(s) of funding:

National Natural Science Foundation of China, No.81973695

研究疾病:

原发性头痛

研究疾病代码:

Target disease:

Primary headache

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究拟通过对治疗肝阳上亢型原发性头痛的合穴处方与常规针刺处方的临床随机对照试验,对比两种处方的临床疗效。

Objectives of Study:

This study intends to compare the clinical efficacy of the two prescriptions through a clinical randomized controlled trial of He-Sea acupoints prescription and routine acupuncture prescription for the treatment of primary headache with liver-yang hyperactivity syndrome.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合原发性头痛的西医和中医诊断标准; (2)年龄18-70岁; (3)男女不限; (4)近1月内未接受与本病相关的各种治疗措施; (5)签署知情同意书,自愿参与并服从课题组安排,坚持完成治疗。

Inclusion criteria

1. Patients who meet the diagnostic criteria of Western medicine and traditional Chinese medicine for primary headache; 2. Patients aged 18-70 years old; 3. Male and female are not limited; 4. Patients who have not received all kinds of treatment measures related to the disease in recent one month; 5. The patients who signed the informed consent form voluntarily participated in and obeyed the arrangement of the research group and insisted on completing the treatment.

排除标准:

(1)孕妇或哺乳期妇女; (2)患有重要器官疾病或其他可能出现严重危及生命的疾病; (3)虽有头痛,但作为其他疾病的伴随症状,如脑外伤后综合征、脑内器质性病变的患者; (4)晕针或过敏体质。

Exclusion criteria:

1. Pregnant or lactating women; 2. Patients suffering from diseases of important organs or other diseases that may seriously endanger life; 3. Patients with headache but accompanied by other diseases, such as post-traumatic brain syndrome and brain organic lesions; 4. Patients with acupuncture sickness or allergic constitution.

研究实施时间:

Study execute time:

From 2021-01-30

To      2022-10-22

征募观察对象时间:

Recruiting time:

From 2021-01-30

To      2022-10-22

干预措施:

Interventions:

组别:

2

样本量:

50

Group:

2

Sample size:

干预措施:

常规针刺处方

干预措施代码:

Routine acupuncture prescription

Intervention:

Routine acupuncture prescription

Intervention code:

组别:

1

样本量:

50

Group:

1

Sample size:

干预措施:

合穴针灸处方

干预措施代码:

He-Sea acupoints prescription

Intervention:

He-Sea acupoints prescription

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学第二附属医院

单位级别:

三级甲等

Institution/hospital:

The Second Affiliated Hospital of Shandong University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

彩色颅内多普勒血流图

指标类型:

主要指标

Outcome:

TCCD

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简明健康调查问卷

指标类型:

次要指标

Outcome:

SF-36

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛症状积分

指标类型:

主要指标

Outcome:

Headache symptom score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三者根据SPSS21.0软件产生随机数字列表,制成随机数字卡片,将卡片分别装入不透明密封袋中,在密封袋上进行编号排序,按研究对象参加试验的前后顺序,有序拆开与之对应的密封袋,再根据密封袋中的数字进行对应的分组,两组人数按照1:1调配,每组50人。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to spss21.0 software, the third party generates a random number list and made it into a random number card. The cards are put into opaque sealed bags and numbered on the sealed bags.

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内,以附件形式公开原始数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data will be made public as an appendix within 6 months after completion of the trial.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data acquisition and management consists of two parts, one is Case Record Form (CRF) and the other is Electronic Data Capture (EDC).

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above